Household level SARS-CoV-2 sero-epidemiology in a high prevalence group of adults and children-implications for community infection control - 22/10/21
Doi : 10.1016/j.ajic.2021.08.015
Alan Werzberger, MD a, b, #, Juan Manuel Carreño, PhD c, #, Sinai Serocore Team c, d, Adam Polinger, MD e, Florian Krammer, PhD c, d, Philip Zachariah, MD, MS, MA b, ⁎ 
a Best Health Care, Monroe, NY
b Department of Pediatrics, Columbia University Irving Medical Center, New York, NY
c Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY
d Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
e Ezras Choilim Health Center, Monroe, NY
⁎Address correspondence to Philip Zachariah, MD, MS, MA, 622 West 168th St, PH4-473, New York, NY 10031.622 West 168th St, PH4-473New YorkNY10031.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Children 10 year and younger are less likely to show evidence of SARS-CoV-2 infection in a household. |
• | Most households have concordant SARS-CoV-2 serostatus between adults and children/adolescents but similar numbers have only a child/adolescent or an adult seropositive. |
• | Households with both adults and children/adolescents positive tend to be larger and have older children. |
Résumé |
In 108 households (n = 474, 280 ≤ 18 years old), SARS-CoV-2 seroprevalence was significantly associated with age (range 37.5%-78.7%) and lowest in children ≤ 10 years old. Among 92 households with members ≤ 18, 14 (15.2%) had only a seropositive child or adolescent, while 16 (17.4%) had only seropositive adults. Households with both groups concurrently seropositive (n = 62) were larger in size (mean 8.11 ± 2.49) vs (mean 5.77 ± 2.31) (P < .001).
Le texte complet de cet article est disponible en PDF.Key Words : COVID-19, Household, Children
Plan
| Funding/Support: Work in the Krammer laboratory for this study was mainly funded directly by the Ezras Choilim Health Center. Work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C and HHSN272201400006C), NIAID grants U01AI141990 and U01AI150747, by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384), and by anonymous donors. This project was also funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract 75N91019D00024, task order 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. |
|
| Conflicts of Interest: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. |
© 2021
Association for Professionals in Infection Control and Epidemiology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 49 - N° 11
P. 1438-1440 - novembre 2021 Retour au numéro
Article précédent
- Environmental testing for SARS-CoV-2 in three tertiary-care hospitals during the peak of the third COVID-19 wave
- Helena C. Maltezou, Maria Tseroni, Charalampos Daflos, Cleo Anastassopoulou, Antonios Vasilogiannakopoulos, Olga Daligarou, Maria Panagiotou, Evanthia Botsa, Nikolaos Spanakis, Athanasia Lourida, Athanasios Tsakris
- High rate of Multidrug-Resistant Organisms (MDROs) among COVID-19 patients presenting with bacteremia upon hospital admission
- Ashish Bhargava, Kathleen Riederer, Mamta Sharma, Elisa Akagi Fukushima, Leonard Johnson, Louis Saravolatz
Bienvenue sur EM-consulte, la référence des professionnels de santé.